A important advancement in glucose management is emerging with the approval of tirzepatide at a dosage of 45mg. This new offering builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://bookmarkrange.com/story23176951/revolutionary-approach-tirzepatide-45mg-for-glucose-management